Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Publicly Releases Data for 120,000 SNPs

NEW YORK, Oct. 10 (GenomeWeb News) - Affymetrix said late yesterday it has publicly released genotype data from 120,000 SNPs selected from the SNP database compiled by Perlegen Sciences, as well as from public databases.

 

The SNP information can be downloaded from Affymetrix's website.

 

The company generated this data using its GeneChip technology. An initial set of approximately 535,000 SNPs from 54 people was tested using the arrays over 8 weeks, to generate about 29  million genotypes. The company then chose the SNPs with "the best distribution across the genome and the highest accuracy and call rates," it said.

 

About half of the SNPs are from the Perlegen database, Stephen Fodor, Affymetrix' chairman and CEO, said in a statement." Over time, we will put all of the SNPs from the Perlegen database into the public domain while also developing products that use both these and public SNPs," Fodor said. "We believe this will aid and complement the public/private haplotype map effort led by the National Human Genome Research Institute."

 

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.